Emerging drugs for irritable bowel syndrome

Chander Shekhar, Peter J. Whorwell

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Irritable bowel syndrome is extremely common and its severity is widely underestimated. Unfortunately, the current pharmacological treatment of this condition is far from satisfactory which might suggest that it would be an area in which the pharmaceutical industry would take a great interest. However, drug development in this field, especially in relation to 5-hydroxytryptamine (5-HT), has been beset by difficulties with side effects and, what some authorities would claim, an unnecessarily strict regulatory climate based on the perception that irritable bowel syndrome is not a particularly serious condition. This has resulted in a rapid withdrawal from the scene by a number of companies although with the identification of some potential new therapeutic targets, the area has not been totally abandoned. © 2009 Informa UK Ltd.
    Original languageEnglish
    Pages (from-to)673-685
    Number of pages12
    JournalExpert Opinion on Emerging Drugs
    Volume14
    Issue number4
    DOIs
    Publication statusPublished - Dec 2009

    Keywords

    • 5-HT
    • Benzodiazepine
    • CCK
    • Channelopathies
    • Chloride channel
    • CRH
    • Guanylate cyclase
    • IBS
    • Neurokinin
    • Opioid
    • Probiotics

    Fingerprint

    Dive into the research topics of 'Emerging drugs for irritable bowel syndrome'. Together they form a unique fingerprint.

    Cite this